Geode Capital Management
RNAM

Geode Capital Management’s Avidity Biosciences RNAM Stock Holding History

Geode Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,120,780
Closed -$225M – 4584
2025
Q4 		$225M Buy
3,120,780
+262,731
+9% +$17M 0.01% 674
2025
Q3 		$125M Buy
2,858,049
+10,084
+0.4% +$408K 0.01% 938
2025
Q2 		$80.9M Buy
2,847,965
+92,719
+3% +$2.76M 0.01% 1148
2025
Q1 		$81.4M Sell
2,755,246
-52,209
-2% -$1.63M 0.01% 1094
2024
Q4 		$82.8M Buy
2,807,455
+222,152
+9% +$9.28M 0.01% 1114
2024
Q3 		$119M Buy
2,585,303
+328,606
+15% +$14.3M 0.01% 872
2024
Q2 		$92.2M Buy
2,256,697
+657,023
+41% +$18.9M 0.01% 970
2024
Q1 		$40.8M Buy
1,599,674
+52,460
+3% +$822K ﹤0.01% 1494
2023
Q4 		$14M Buy
1,547,214
+111,661
+8% +$746K ﹤0.01% 2134
2023
Q3 		$9.16M Sell
1,435,553
-2,997
-0.2% -$25.8K ﹤0.01% 2323
2023
Q2 		$16M Buy
1,438,550
+136,517
+10% +$1.71M ﹤0.01% 2011
2023
Q1 		$20M Buy
1,302,033
+179,655
+16% +$3.95M ﹤0.01% 1802
2022
Q4 		$24.9M Buy
1,122,378
+182,754
+19% +$2.72M ﹤0.01% 1627
2022
Q3 		$15.3M Buy
939,624
+90,923
+11% +$1.74M ﹤0.01% 1931
2022
Q2 		$12.3M Buy
848,701
+111,605
+15% +$1.66M ﹤0.01% 2107
2022
Q1 		$13.6M Buy
737,096
+22,855
+3% +$388K ﹤0.01% 2141
2021
Q4 		$17M Sell
714,241
-25,025
-3% -$598K ﹤0.01% 2070
2021
Q3 		$18.2M Buy
739,266
+326,589
+79% +$7.1M ﹤0.01% 2032
2021
Q2 		$10.2M Buy
412,677
+7,003
+2% +$163K ﹤0.01% 2441
2021
Q1 		$8.85M Buy
405,674
+140,086
+53% +$3.43M ﹤0.01% 2438
2020
Q4 		$6.78M Sell
265,588
-5,049
-2% -$147K ﹤0.01% 2413
2020
Q3 		$7.62M Buy
270,637
+253,706
+1,498% +$7.33M ﹤0.01% 2134
2020
Q2 		$478K Buy
+16,931
New +$488K ﹤0.01% 3396

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Geode Capital Management's RNAM Position: Q1 2026 in Review

Geode Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,120,780 shares — an estimated $225M sold.

Geode Capital Management first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $225M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Geode Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 3,120,780 Avidity Biosciences shares in Q1 2026, an estimated $225M.
  • Geode Capital Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
  • Geode Capital Management's Avidity Biosciences position peaked at $225M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.